The global general anesthesia drugs industry is on the brink of a significant upsurge, with estimations pointing towards a substantial leap from its 2023 valuation of US$ 4,978.1 million to a forecasted US$ 6,898.4 million by 2033. Market analysts project this growth to be driven by an expected demand increase, albeit at a moderate Compound …